Duchenne Muscular Dystrophy Clinical Trial
— DuchenneOfficial title:
Remote Physiotherapy Application to Protect Physical Health in Duchenne Muscular Dystrophy
Verified date | March 2022 |
Source | Karadeniz Technical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Duchenne Muscular Dystrophy (DMD) is a progressive inherited disease that affects the muscles and causes functional limitations to varying degrees. It is vital to start physiotherapy follow-ups immediately after diagnosis. Patients with DMD are among the most vulnerable groups who have problems in accessing physiotherapy services during the COVID-19 pandemic. The aim of the study was to investigate the effects of the telerehabilitation program developed to protect the physical health of patients with DMD and not to interrupt their follow-up.
Status | Completed |
Enrollment | 43 |
Est. completion date | January 1, 2022 |
Est. primary completion date | November 15, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 5 Years and older |
Eligibility | Inclusion Criteria: - Able to communicate verbally and visually - Older than 5 years old Exclusion Criteria: - The children who had undergone any surgical operations in the past 6 months, - Having a severe cognitive and breathing impairment - Using mechanical ventilator continually or intermittent - Having a febrile infection |
Country | Name | City | State |
---|---|---|---|
Turkey | Karadeniz Technical University | Trabzon | Ortahisar |
Lead Sponsor | Collaborator |
---|---|
Karadeniz Technical University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional level | Brooke Function Classification System | Before the intervention, up to one month | |
Primary | Socio-demographics | gender, body weight, height | Before the intervention, up to one month | |
Primary | Walking test (Before intervention) | The distance of 10 m was determined in a suitable indoor environment. | Before the intervention, up to one month. | |
Primary | Walking test (After intervention) | The distance of 10 m was determined in a suitable indoor environment. | After the intervention, average two weeks. | |
Primary | Time to stand up from the supine position (Before intervention) | The time to stand up from the supine position was recorded. | Before the intervention, up to one month. | |
Primary | Time to stand up from the supine position (After intervention) | The time to stand up from the supine position was recorded. | After the intervention, average two weeks. | |
Primary | Modified upper extremity performance test (Before intervention) | Flexion the shoulder to 90 degrees, flexion the shoulder above 90 degrees (above eye level), abduction of the shoulder 90 degrees, abduction of the shoulder above 90 degrees, doing the same movements with weight, bringing the empty glass to the mouth in a sitting position, bringing the full glass to the mouth | Before the intervention, up to one month. | |
Primary | Modified upper extremity performance test (After intervention) | Flexion the shoulder to 90 degrees, flexion the shoulder above 90 degrees (above eye level), abduction of the shoulder 90 degrees, abduction of the shoulder above 90 degrees, doing the same movements with weight, bringing the empty glass to the mouth in a sitting position, bringing the full glass to the mouth | After the intervention, average two weeks. | |
Primary | Endurance (Before intervention) | The number of knee extensions and elbow flexions they can do in sitting position in 30 seconds | Before the intervention, up to one month. | |
Primary | Endurance (After intervention) | The number of knee extensions and elbow flexions they can do in sitting position in 30 seconds | After the intervention, average two weeks. | |
Primary | Pulmonary Dysfunction Test (Before intervention) | Value when the patient counts audibly in a single expiration after maximum inspiratory effort | Before the intervention, up to one month. | |
Primary | Pulmonary Dysfunction Test (After intervention) | Value when the patient counts audibly in a single expiration after maximum inspiratory effort | After the intervention, average two weeks. | |
Secondary | Patient Satisfaction Survey | General satisfaction, internet/connection, physiotherapist's guidance, timing, level of knowledge, reassurance, comfort, knowledge/advice, level of satisfaction with information clarity | After the intervention average two weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05575648 -
Dual Task in Duchenne Muscular Dystrophy
|
N/A | |
Terminated |
NCT03907072 -
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450639 -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Active, not recruiting |
NCT04906460 -
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02500381 -
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 3 | |
Enrolling by invitation |
NCT05967351 -
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
|
Phase 3 | |
Recruiting |
NCT03067831 -
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02246478 -
A Study of TAS-205 for Duchenne Muscular Dystrophy
|
Phase 1 | |
Active, not recruiting |
NCT01772043 -
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
|
N/A | |
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT00758225 -
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
|
Phase 2 | |
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Recruiting |
NCT03513367 -
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
|
||
Recruiting |
NCT05712447 -
Duchenne Muscular Dystrophy Video Assessment Registry
|
||
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT03319030 -
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
|
||
Terminated |
NCT01753804 -
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
|
N/A | |
Completed |
NCT02530905 -
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
|
Phase 1 |